Global trade policy and geopolitical tensions are reshaping the pharmaceutical supply chain in ways that will define drug manufacturing for years to come. From tariff-driven decisions about where to source and produce, to the ripple effects of US/Iran tensions on critical supply routes, pharma leaders are navigating a landscape that is creating both immediate challenges and longer-term strategic questions.

‍

Join us for a complimentary webcast examining how global trade policies and geopolitical tensions are disrupting the pharmaceutical supply chain and what it means for drug manufacturing today and in the future, including:

‍

Trade Policies and Tariffs: Diversification of drug manufacturing across countries versus single-country production and sourcing - the tradeoffs and strategic implications
US/Iran Tensions: Current and potential future impacts to the pharmaceutical supply chain
Global Political Tensions: Potential regulatory and government clashes, including discord between the FDA and European agencies
Cross-Industry Lessons: How other industries have navigated similar supply chain disruptions and what pharma can learn from their responses

‍

Featuring James Doyle, Founder & CEO at Boston Warwick

‍

Please note, James Doyle will not discuss Boston Warwick Ltd or his consulting work. James Doyle may have limitations on what he is permitted to discuss about his former employers, and will decline to answer questions related to confidential matters.

‍

Pharma supply chain under pressure | Trade policy, geopolitical risk, and what comes next